Fedratinib, an oral, potent JAK2 inhibitor effective against wild-type and mutationally activated JAK2 and fms-like tyrosine kinase 3 (FLT3), was approved in 2019 for treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis [68]. The gene discussed is FLT3; the disease is myelofibrosis.